OptimizeRx (OPRX) Receivables - Other (2016 - 2025)
OptimizeRx (OPRX) has disclosed Receivables - Other for 10 consecutive years, with $3.9 million as the latest value for Q4 2025.
- Quarterly Receivables - Other rose 21.66% to $3.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.9 million through Dec 2025, up 21.66% year-over-year, with the annual reading at $3.9 million for FY2025, 21.66% up from the prior year.
- Receivables - Other hit $3.9 million in Q4 2025 for OptimizeRx, up from $3.7 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $6.1 million in Q4 2023 to a low of $2.1 million in Q4 2021.
- Historically, Receivables - Other has averaged $4.0 million across 5 years, with a median of $3.7 million in 2025.
- Biggest five-year swings in Receivables - Other: soared 178.77% in 2021 and later tumbled 46.67% in 2024.
- Year by year, Receivables - Other stood at $2.1 million in 2021, then surged by 69.73% to $3.6 million in 2022, then skyrocketed by 69.62% to $6.1 million in 2023, then plummeted by 46.67% to $3.2 million in 2024, then rose by 21.66% to $3.9 million in 2025.
- Business Quant data shows Receivables - Other for OPRX at $3.9 million in Q4 2025, $3.7 million in Q3 2025, and $3.5 million in Q2 2025.